Results were presented at Transcatheter Cardiovascular Therapeutics, or TCT, 2024 conference from the first completed pivotal trial on patients supported with Impella ECP, a novel transvalvular axial flow pump with compressible pump architecture. Impella ECP is a technology of Abiomed, part of Johnson & Johnson MedTech, the company noted. The pivotal investigational device exemption study, which enrolled 256 patients at 18 sites in the US, met the primary endpoint. MACCE, or Major Adverse Cardiac and Cerebrovascular Events, rate at 30 days was 6.3%, significantly below the pre-defined performance goal, the company announced. “The study demonstrated Impella ECP’s safety and efficacy for use in high-risk PCI. Operators chose 8Fr Angio-Seal as the first-closure method in 70% of the patients, with a 92% success rate,” the company stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on JNJ:
- Johnson & Johnson’s Tremfya shows efficacy in Crohn’s disease Phase 3 study
- Johnson & Johnson reports results from Phase 3b SPECTREM study
- Halozyme provides update following EPO decision to revoke Darzalex patent
- Kenvue price target raised to $27 from $24 at BofA
- Boeing machinists announce proposal to end strike: Morning Buzz
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
